🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the EU / 2026-525464-18-00
Authorised Phase I

Safety and Tolerability of REGN17235 in Adult Participants with Clonal Cytopenia of Undetermined Significance and Low-Risk Myelodysplastic Syndrome with SF3B1 Mutation

2026-525464-18-00 · tracked via the Priya Life Science EU tracker
Sponsor
Regeneron Pharmaceuticals Inc.
Sponsor type
Pharmaceutical company
Therapeutic area
Neoplasms
Decision date
22/06/2026
Enrollment target
15
Sites
Belgium

Condition studied

Clonal Cytopenia of Undetermined Significance with SF3B1 mutation, Low-Risk Myelodysplastic Syndrome with SF3B1 mutation

Eligibility

Age group
65+ years, 18-64 years
Sex
Female, Male
Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2026-525464-18-00 on CTIS ↗ ← All trials in the EU